X4 Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 11, 2026, specifically the Company's Annual Meeting of Stockholders. The meeting was held at 12:00 p.m. Eastern Time with a quorum present. As of the record date (March 13, 2026), there were 90,919,696 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Stockholder Votes
The filing details the final results of four proposals submitted to stockholders:
- Proposal 1 (Election of Directors): Stockholders elected three Class III director nominees (Gary J. Bridger, Françoise De Craecker, and Michael S. Wyzga) to serve until the 2029 Annual Meeting. All nominees received significant "For" votes, ranging from approximately 71.7 million to 73.4 million.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was overwhelmingly in favor (82,734,674 For vs. 68,992 Against).
- Proposal 3 (Equity Incentive Plan): Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan. This approval increases the number of shares available for issuance under the Plan by 1,500,000 shares. The vote was 58,679,552 For and 17,684,140 Against.
- Proposal 4 (Say-on-Pay): Stockholders approved, on a non-binding advisory basis, the compensation of the named executive officers. The vote was 70,932,142 For and 5,420,569 Against.
Guidance, Outlook, and Risks
This filing does not contain management guidance, future outlook, risk factors, or discussion of contingencies. It strictly reports the outcomes of the Annual Meeting and the approval of the amended equity plan.
Key Facts for Investor Verification
- Verify the impact of the 1,500,000 share increase to the 2017 Equity Incentive Plan on potential future dilution.
- Note the significant number of votes cast Against Proposal 3 (Equity Plan), totaling 17,684,140, which may indicate stockholder sentiment regarding equity dilution.
- Confirm the tenure of the newly elected directors, who will serve until the 2029 Annual Meeting.
- Review the full text of the Second Amended and Restated 2017 Equity Incentive Plan filed as Exhibit 10.1 for specific terms and conditions.